TFRC and gastric carcinoma: First and foremost, its dual-targeting architecture capitalizes on the co-overexpression of CD71 and Claudin18.2 in gastric carcinoma cells, achieving a 25-fold enhancement in cellular internalization compared to single-target probes (Fig. 3F).